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A double homozygous mutation in the POMT1 gene involving exon skipping 
gives rise to Walker-Warburg syndrome in two Spanish Gypsy families 
 
To the Editor : 
 
Alpha-dystroglycanopathies are a large group of autosomal recessive muscular 
dystrophies that involve defects in α-dystroglycan (α-DG) Oglycosylation. 
Walker–Warburg syndrome (WWS, OMIM 236670) is the most severe alpha-
dystroglycanopathy, and affected infants rarely survive past the first year of life. The 
phenotype mainly involves muscle, eye and brain abnormalities associated 
with anomalous neuronal migration, and it overlaps with Fukuyama congenital muscular 
dystrophy (FCMD, OMIM 253800) and muscleeye-brain (MEB) disease (OMIM 253280), 
other severe alpha-dystroglycanopathies. Mutations in six genes are known to cause 
alphadystroglycanopathies, all encoding known or putative glycosyltransferases: POMT1, 
POMT2, POMGnT1, fukutin, FKRP and LARGE. 
Mutations in POMT1 are responsible for approximately 25% of WWS cases and its 
targeted disruption in mice provokes embryonic lethality. Murine Pomt1 is predominantly 
expressed in the tissues most severely affected in WWS patients, this expression 
persisting in the muscles, eyes, brain and cerebellum. 
Here, we describe a double homozygous mutation in the POMT1 gene in two unrelated 
Gypsy families, reflecting the often higher incidence of recessive diseases in endogamic 
populations. 
Family1. Two affected male siblings, patients 1.1 and 1.2, were born to second-degree 
cousins in a Spanish Gypsy family. Patient 1.1 had profound muscular hypotonia at birth 
and a creatine kinase (CK) value of 8,400 IU/l. Muscular dystrophy was later confirmed by 
biopsy although merosin appeared normal. The infant showed retromicrognatia, low 
implanted ears, microphthalmia, cataract, microcornia and retinal dysplasia. Brain MRI 
identified type II lyssencephaly, hydrocephalus, agenesis of the corpus callosum, 
hypomyelination, cerebellar and brain stem hypoplasia, and Dandy–Walker malformation. 
He died at 4 months. Patient 1.2 displayed similar symptoms and had a similar 
appearance to his brother, but there are no biological samples and his age of death was 
not determined. 
Family2. This affected male sibling, patient 2.1, was born to double first-degree cousins in 
a Spanish Gypsy family. The patient had profound paralysing muscle hypotonia and a CK 
value of 40,851 IU/L at birth. Muscle biopsy confirmed muscular dystrophy although 
merosin appeared normal. Ocular examination revealed microphthalmia and bilateral 
retinal detachment. The patient also exhibited hypertelorism, frontal bossing and low 
implanted ears. Brain MRI showed lissencephaly, hydrocephalus, agenesis of the septum 
pellucidum and of the posterior corpus callosum, and cerebellar hypoplasia. The patient 
died 10 days after birth. 
Analysis of the complete coding region of the POMT1 gene revealed a double 
homozygous mutation in both patients in reference to the most common POMT1 splice 
variant (NM_001077 365.1) (13). The first homozygous mutation, g.3553G>T 
(NC_000009.10), was found at the beginning of intron 4 at the exon–intron boundary 
(Fig. 1Aa). Indeed, the mutation produced the loss of the entire exon 4 in mRNA 
transcripts from patients 1.1 and 2.1. As this loss of 17 amino acids did not alter the 
reading frame, the ensuing protein has 708 instead of 725 amino acids. Exon 4 is located 
at Loop 1 of the POMT1 protein, within the conserved pfam02366 domain (protein 
mannosyltransferase, PMT) that potentially influences the protein’s catalytic activity. This 
exon is highly conserved, with significant amino acid sequence identity, supporting 
information online), and it is the same size in all studied organisms. 
The second homozygous mutation found, c.1545C>G, predicts the p.Ser515Arg 
substitution in exon 16 of POMT1, a serine only conserved from birds to humans. The 
same substitution has already been described in heterozygosity in an American WWS 
patient, although no additional mutations were found in this patient to account for the 
WWS phenotype. Recently, this mutation was found in heterozygosity in an Italian patient 
diagnosed with congenital muscular dystrophy and mental retardation who also carried 
another mutation in the POMT1 coding region, raising the possibility that this is a hot-
mutation site in the gene. 
Western blotting revealed a complete lack of glycosylated α-DG, which was confirmed by 
laminin overlay assay, while β-DG detection was normal (data not shown). 
Immunohistochemical analysis of muscle biopsies with VIA-4 antibody corroborated 
the alpha-dystroglycanopathy in both patients. However, the α-DG core protein was 
correctly located at the plasma membrane as assessed by the pαDAG antibody and 
distributed within the cell, probably undergoing post-translational modifications. 
Immunolabelling of β-DG and laminin was normal. 
POMT1 is an integral endoplasmic reticulum (ER) membrane protein distributed in a 
similar pattern to the ER-marker calnexin. In muscle cells, the sarcoplasmic reticulum (SR) 
forms a network around the transverse T tubules that is continuous with the plasma 
membrane. In controls, POMT1 and calnexin were detected in the SR as part of this 
network within the muscle cell, as well as in the subsarcolemic space. While the 
distribution of calnexin did not appear to change in patients 1.1 and 2.1, POMT1 was 
only located in certain parts of the subsarcolemma and diffusely within the cell. 
The mutation g.3553G>T removes exon 4 from the POMT1 transcript of patients 1.1 and 
2.1 while preserving the open reading frame and the epitope recognized by the anti-
POMT1 antibody in Loop 5. Nevertheless, the distribution of POMT1 is altered, and it no 
longer co-localizes with calnexin, implying it has lost its ER-localization. This could be due 
to conformational changes in the POMT1 protein or to the degradation of the mutated 
protein inside the muscle cell. Staining for calnexin dismisses any major alterations to the 
SR in these patients. 
Of these two mutations, the one causing exon 4 skipping is likely to be the most relevant 
for the WWS phenotype. In the second mutation, the substituted Ser515 is not very 
conserved and patients carrying this mutation do not provide much information about its 
relevance as none are homozygous carriers. Thus, although disease causing, this 
mutation might be responsible for milder phenotypes if not accompanied by a more 
severe change. 
Founder effects have been reported for genes causing dystroglycanopathies in close-knit 
populations and less so in families with no defined inbreeding. We recently reported a 
potential founder mutation in the fukutin gene in the Ashkenazi Jewish population that was 
subsequently confirmed in a larger study. Since both our subjects carrying the same 
homozygous mutations belong to unrelated Gypsy families, the mutations identified here 
could reflect a possible founder effect in the POMT1 gene within the Spanish Gypsy 
population. Patients 1.1 and 2.1 came from families with a high degree of consanguinity 
and thus, it is likely that the parents of both patients were heterozygous carriers of the 
mutations. Unfortunately, no samples from the parents were available for studies. 
Inbreeding is very common in the Gypsy population, manifesting a high prevalence of 
phenotypes caused by recessive mutations and the transmission of these mutations. 
Further studies will be necessary to determine if this double mutation in the POMT1 
gene is widespread among the Spanish Gypsy population. 
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